Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darifenacin in older adults with overactive bladder
2004-002894-21Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing EMSELEX with Placebo (2 arms). Primary endpoint: Change from baseline in urge urinary incontinence episodes per week at week 12. Started Mar 2005; status: completed.
02
Drugs
darifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2004-002894-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002894-21.